Sustanon 250 250 mg/ml solution for injection

Sustanon

Prescription-only androgen replacement medicine

Testosterone injection (ester blend)

UK marketing authorisation PL 39699/0059 held by Aspen Pharma Trading Limited. :contentReference[oaicite:27]{index=27}
Regulated prescription Only medicine under UK law. :contentReference[oaicite:28]{index=28}
ATC code G03BA03 (Androgens) under WHO classification. :contentReference[oaicite:29]{index=29}

UK marketing authorisation PL 39699/0059 held by Aspen Pharma Trading Limited. :contentReference[oaicite:27]{index=27}
Regulated prescription Only medicine under UK law. :contentReference[oaicite:28]{index=28}
ATC code G03BA03 (Androgens) under WHO classification. :contentReference[oaicite:29]{index=29}

Testosterone injection (ester blend)

Description

Sustanon 250 is an oil‑based injectable testosterone formulation containing a blend of four testosterone esters (testosterone propionate, phenylpropionate, isocaproate and decanoate) in a 250 mg/ml solution, used to provide sustained testosterone release over weeks instead of days. It is indicated for testosterone replacement therapy in men with confirmed hypogonadism, and may also be used in female‑to‑male transsexuals under specialist supervision. :contentReference[oaicite:1]{index=1}

Bnefits

Restores serum testosterone in men with testosterone deficiency (hypogonadism)
Helps improve symptoms related to low testosterone: low libido, fatigue, muscle mass loss, bone density loss, etc. :contentReference[oaicite:2]{index=2}
Long‑acting formulation (blend of esters) allows less frequent injections compared with short‑acting testosterone preparations (e.g. every 3 weeks typical regimen) :contentReference[oaicite:3]{index=3}
May be used in gender‑affirming hormone therapy (female‑to‑male) under specialist supervision. :contentReference[oaicite:4]{index=4}

Indications

Testosterone replacement therapy in adult men with confirmed hypogonadism (primary or secondary) when testosterone deficiency is clinically and biochemically established. :contentReference[oaicite:5]{index=5}
Supportive therapy for female‑to‑male transsexuals (gender-affirming hormone therapy). :contentReference[oaicite:6]{index=6}

Composition

Testosterone propionate 30 mg per ml
Testosterone phenylpropionate 60 mg per ml
Testosterone isocaproate 60 mg per ml
Testosterone decanoate 100 mg per ml
Total testosterone content equivalent to ≈ 176 mg per ml of solution. :contentReference[oaicite:7]{index=7}
Excipients: Arachis oil (refined peanut oil), Benzyl alcohol (preservative) :contentReference[oaicite:8]{index=8}

Formulation

Solution for intramuscular injection
Clear, pale yellow oily solution in 1 mL glass ampoule. :contentReference[oaicite:9]{index=9}

Packaging

1 mL glass ampoule containing 250 mg/ml testosterone solution (Sustanon 250) per ampoule. Box contains 1 ampoule (other pack sizes may not be marketed). :contentReference[oaicite:10]{index=10}

Usage

Administer by deep intramuscular injection (e.g. buttock, upper leg or upper arm). :contentReference[oaicite:11]{index=11}
Typical dose for testosterone replacement therapy: 1 mL every 3 weeks in adult men. :contentReference[oaicite:12]{index=12}
Dosing should be individually adjusted based on clinical response and regular monitoring of hormone levels. :contentReference[oaicite:13]{index=13}

Contraindications

Known or suspected carcinoma of the prostate or male breast cancer. :contentReference[oaicite:16]{index=16}
Pregnancy or breastfeeding (in women). :contentReference[oaicite:17]{index=17}
Hypersensitivity to any active substance or excipient (including peanut/soya allergy due to arachis oil). :contentReference[oaicite:18]{index=18}
Children under 3 years (due to benzyl alcohol preservative). :contentReference[oaicite:19]{index=19}

Adverse Effects

Increase in red blood cell count, haemoglobin and haematocrit (possible polycythaemia). :contentReference[oaicite:20]{index=20}
Injection site reactions. :contentReference[oaicite:21]{index=21}
Acne, oily skin, increased body or facial hair, possible male pattern baldness. :contentReference[oaicite:22]{index=22}
Water retention / fluid retention and possible changes in lipid profile (cholesterol). :contentReference[oaicite:23]{index=23}
Mood changes, changes in sleep, possibly other androgen-related systemic effects. :contentReference[oaicite:24]{index=24}

Storage Conditions

Store below 30 °C, do not refrigerate or freeze. :contentReference[oaicite:25]{index=25}
Store in original package, protected from light. :contentReference[oaicite:26]{index=26}

Duration

Individualised \u2014 generally long-term maintenance therapy under medical supervision; dosing every ~3 weeks, reviewed periodically. :contentReference[oaicite:14]{index=14}